Literature DB >> 18796529

What is the most important outcome parameter in ankylosing spondylitis?

J Braun, J Sieper.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18796529     DOI： 10.1093/rheumatology/ken357

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Comparison of rates of referral and diagnosis of axial spondyloarthritis before and after an ankylosing spondylitis public awareness campaign.

Authors:  Andrew A Harrison; Christoffel Badenhorst; Sandra Kirby; Douglas White; Josie Athens; Simon Stebbings
Journal:  Clin Rheumatol       Date:  2014-03-11       Impact factor: 2.980

2.  [Spondyloarthritides].

Authors:  J Braun; M Rudwaleit; J Sieper
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

Review 3.  Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.

Authors:  Heiner Appel; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

4.  Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial.

Authors:  Fabian Proft; Anja Weiß; Murat Torgutalp; Mikhail Protopopov; Valeria Rios Rodriguez; Hildrun Haibel; Olaf Behmer; Joachim Sieper; Denis Poddubnyy
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-01-29       Impact factor: 5.346

5.  Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).

Authors:  Joachim Sieper; Jürgen Braun; Jonathan Kay; Salvatore Badalamenti; Allen R Radin; Lixia Jiao; Stefano Fiore; Tanya Momtahen; George D Yancopoulos; Neil Stahl; Robert D Inman
Journal:  Ann Rheum Dis       Date:  2014-02-18       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.